Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Nov;15(11):1347-53.
doi: 10.1016/j.bbmt.2009.07.015.

Dichotomous role of interferon-gamma in allogeneic bone marrow transplant

Affiliations
Review

Dichotomous role of interferon-gamma in allogeneic bone marrow transplant

Ying Lu et al. Biol Blood Marrow Transplant. 2009 Nov.

Abstract

Interferon (IFN)-gamma is a pleiotropic cytokine with a central role in innate and adaptive immunity. As a potent pro-inflammatory and antitumor cytokine, IFN-gamma is conventionally thought to be responsible for driving cellular immune response. On the other hand, accumulating evidence suggests that IFN-gamma also has immunosuppressive activity. An important role for IFN-gamma in inhibiting graft-versus-host disease (GVHD) has been demonstrated in murine models, despite IFN-gamma being one of the key factors amplifying T cell activation during the process of acute GVHD (aGVHD), the major complication and cause of post-transplant mortality in allogeneic bone marrow transplantation (BMT). At the same time, IFN-gamma facilitates graft-versus-leukemia (GVL) activity. Dissociation of GVL effects from GVHD has been the ultimate goal of allogeneic BMT in the treatment of hematologic malignancies. This paradoxic role of IFN-gamma makes modulating its activity a promising strategy to maximize GVL while minimizing GVHD and improve clinical outcomes in BMT. In this review, the effects of IFN-gamma on GVHD and GVL are discussed with consideration of the mechanism of IFN-gamma action.

PubMed Disclaimer

Figures

Figure 1
Figure 1. IFN-γ-producing cells show different effects on GVHD and GVL
increase; ⊝ inhibit; formula image unknown
Figure 2
Figure 2. Role of IFN-γ during the development of GVHD and GVL
The conditioning regimen leads to damage of host tissues and allows the translocation of LPS and other pro-inflammatory cytokines into the circulation, leading to the activation of donor T-cell by host APC[17]. Interaction between donor IL-12-producing APC with donor T cells can increase the IFN-γ production by activated T-cells. High local levels of IFN-γ subsequently induce IDO expression on donor APC [Lu et al. 2009, in preparation]. IDO+ APCs help maintain the tolerant phenotype of T-reg which inhibits the Th1 and Th17 polarization of donor T-cells, resulting in down-modulation of T-cell allo-reactivity and GVHD effect[83].
Figure 3
Figure 3. IFN-γ-induced IDO expression on host epithelial cells inhibits GVHD
Donor T-cells induce GVHD effects that cause target epithelial cell apoptosis [17, 22]. IDO expression on host epithelial cells induced by IFN-γ from donor T-cells inhibits GVHD [85]. In addition, IFN-γ enhances GVL effect through both direct and indirect mechanisms, resulting in apoptosis of tumor cells[18].

References

    1. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol. 1993;11:571–611. - PubMed
    1. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163–189. - PubMed
    1. Frucht DM, Fukao T, Bogdan C, Schindler H, O’Shea JJ, Koyasu S. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 2001;22:556–560. - PubMed
    1. Flaishon L, Hershkoviz R, Lantner F, et al. Autocrine secretion of interferon gamma negatively regulates homing of immature B cells. J Exp Med. 2000;192:1381–1388. - PMC - PubMed
    1. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol. 2000;1:475–482. - PubMed

Publication types

MeSH terms

Substances